Replies to post #116016 on Biotech Values

[DewDiligence]

Re: Rumored Copaxone clinical trial (follow-up to #msg-60673589)

ANDAs for injected drugs ordinarily don’t need bioequivalence studies because such drugs, by definition, don’t have the variability in bioavailability that comes from variability of dissolution in the GI tract. However, it’s conceivable that the FDA may nevertheless want a bioequivalence study for NVS/MNTA’s generic Copaxone. If there is any chance of this, it would make sense for NVS/MNTA to conduct such a study prophylactically rather than getting hit with a deficiency letter later.